Revenue from Patanjali's edible oils segment, which makes up nearly three-fourths of its total revenue, rose 22.5% during the quarter
The development comes after the Food Safety and Standards Authority of India (FSSAI) issued an order to the company to recall an entire batch of the product
In an exchange filing on Thursday, Patanjali stated it had received the order on January 16
A Kerala court has issued a bailable warrant against Patanjali's Ramdev and Balkrishna for publishing misleading ads, following a drug inspector's report on violations of advertising laws
The Delhi High Court has sought Patanjali Ayurved's stand on a lawsuit by Dabur over advertisements allegedly disparaging its product Chyawanprash. On December 24, Justice Mini Pushkarna issued summons on the lawsuit to the defendants -- Patanjali Ayurved and Patanjali Foods Ltd -- for a reply in the matter. "Accordingly, let the plaint be registered as suit. Issue summons.. Let the written statement be filed by the defendants within thirty days from today," the order said. Dabur alleged that while promoting Patanjali Special Chyawanprash, fallacious and deliberate imputations were made, which defamed its product Dabur Chyawanprash -- a market leader with a share of more than 60 per cent. The court also issued notice on an application seeking an interim relief and posted the hearing on January 30. The plea said in the advertisements, the defendants have claimed only Patanjali Special Chyawanprash was the "original" and therefore "special" besides being "shreshtham/sarv-shreshth" o
The lawsuit alleges that an advertisement featuring Patanjali Ayurved founder Baba Ramdev falsely claims that only Patanjali's Chyawanprash is 'original'
The Ruchi Gold oil maker's profit rose to Rs 309 crore (about $37 million) for the three months ended Sept. 30, from Rs 255 crore a year earlier
India is the world's largest importer and meets 70% of its vegetable oil demand through foreign sourcing
Patanjali Foods share price: Reports said Promoter entities Patanjali Ayurved, and Patanjali Parivahan were looking to sell up to 11 million shares in the company
The Delhi High Court on Friday sought the Centre's stand on a petition seeking action against the alleged misbranding of Patanjali's "Divya Dant Manjan" as a vegetarian product. The petitioner's counsel claimed that though the dental care product was being sold with a "green dot", symbolising that it was a vegetarian commodity, it contains fish extract, a non-vegetarian ingredient. Justice Sanjeev Narula issued notice to the Centre, the Food Safety and Standards Authority of India (FSSAI) as well as Patanjali, Divya Pharmacy, Yoga guru Ramdev and other related parties on the petition by lawyer Yatin Sharma. The law does not mandate declaration of a "drug" as vegetarian or non-vegetarian but the packaging of "Divya Dant Manjan" wrongly carries a "green dot", which qualifies as "misbranding" under the Drugs and Cosmetics Act, the petitioner's counsel argued. The matter would be heard next in November. Represented by advocates Swapnil Chaudhary and Prashant Gupta, the petitioner stat
'Rule 170 of Drugs and Cosmetic Rules 1945, which deals with prohibition of misleading advertisement of Ayurveda, Siddha or Unani drugs, shall remain in the statute book'
On the weekly chart, Patanjali has previously faced notable resistance near the Rs 1,700 level. However, despite challenging market conditions this week, the stock has experienced a significant break
Patanjali misleading ads case: The Supreme Court ordered IMA President RV Asokan to issue apology in leading newspapers and to cover its cost himself
With a strong presence in the hinterland, Patanjali Foods is positive about rural demand moving northwards in the coming quarter.
Licences for 14 Ayurvedic products by Patanjali and Divya Pharmacy were suspended by the Uttarakhand government. However, on July 1, the state government revoked its suspension order
Court says disparaging claims undermine ayurveda's credibility
The sale of 14 Ayurvedic medicines manufactured by Divya Pharmacy and Patanjali Ayurveda Limited has been banned by the Gautam Buddh Nagar administration. The Supreme Court on July 9 directed Patanjali Ayurved Ltd, founded by yoga guru Ramdev, to file an affidavit stating whether advertisements of its 14 products, whose manufacturing licences were initially suspended but later restored, have been withdrawn. The Uttarakhand State Licensing Authority had on April 15 issued an order suspending the manufacturing licences of 14 products of Patanjali Ayurved Ltd and Divya Pharmacy. The Regional Ayurvedic and Unani Officer of Gautam Buddh Nagar issued the directive banning the 14 products on Friday, officials said. This action follows orders from the State Drug Licensing Authority, Ayurvedic and Unani Services, Uttarakhand, they said. According to information shared by the district information office, all medical practitioners and medical stores operating in the district have been inform
The Bombay High Court has directed Patanjali Ayurved to deposit Rs 50 lakh for alleged breach of the HC's interim order restraining it from selling its camphor products, in relation to a trademark infringement case filed by another company. Following trademark infringement allegations by Mangalam Organics Ltd, the HC in an interim order in August 2023 restrained Patanjali Ayurved Ltd from selling its camphor products. A single bench of Justice R I Chagla on July 8 noted that Patanjali, in an affidavit submitted in June, admitted breach of the earlier order granting injunction against sale of the impugned camphor products. "Such persistent breach of the injunction order dated 30th August 2023 by defendant no. 1 (Patanjali) cannot be tolerated by this court," Justice Chagla said in the order, a copy of which was made available on Wednesday. The bench said it would be appropriate to direct Patanjali to deposit a sum of Rs 50 lakh prior to passing of an order for contempt/breach of the
Patanjali tells Supreme Court it has stopped selling 14 products whose manufacturing licences were suspended in Uttarakhand
The company has also entered a licensing agreement with Patanjali Ayurved for a 3 per cent turnover-based fee